SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Monogram Technologies Inc. (Nasdaq – MGRM)

BALA CYNWYD – July 14, 2025/Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Monogram Technologies Inc. (“Monogram” or the “Company”) (Nasdaq – MGRM) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Zimmer Biomet Holdings, Inc. (“Zimmer”) (NYSE – ZBH). Under the terms of the transaction, Zimmer will acquire all outstanding shares of stock of Monogram for an upfront payment of $4.04 per share in cash, corresponding to an equity value of approximately $177 million and an enterprise value of approximately $168 million. Monogram common stockholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share of common stock in cash if certain product development, regulatory and revenue milestones are achieved through 2030.

If you own shares of Monogram stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.